Literature DB >> 11961435

Multiple pulmonary arterial aneurysms in Behçet's disease: clinical and radiologic remission after cyclophosphamide and corticosteroid therapy.

Serir Aktoğu1, Onur Fevzi Erer, Gülcan Urpek, Omer Soy, Gültekin Tibet.   

Abstract

Behçet's disease (BD) with pulmonary arterial aneurysm is rare and often associated with a poor prognosis. But there is also a chance that the aneurysm may completely resolve with medical therapy. A 39-year-old man presented with fever, malaise, bilateral chest pain, recurrent oral ulcers, and hemoptysis. The chest radiograph showed a round opacity in the right hilum. Computed tomography and magnetic resonance angiography (MRA) further revealed multiple, bilateral pulmonary arterial aneurysms consistent with the diagnosis of BD. The patient was started on a course of cyclophosphamide and corticosteroid therapy that resulted in cessation of his symptoms and complete resolution of radiologic findings. The chest radiograph and MRA reverted to normal on long-term follow-up. He is still alive and symptom-free 20 months after diagnosis. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11961435     DOI: 10.1159/000056324

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  3 in total

1.  Multiple Right and Left Pulmonary Arteries and Subdivisions of Inferior Mesenteric Artery Aneurysms in Behcet's Disease Case: A Rare Clinical Presentation.

Authors:  Reza Faridhosseini; Farah Jabbari; Afshin Shirkani; Mohammad Reza Zandkarimi; Hadis Yousefzaedh; Maryam Sahebari; Reza Basiri
Journal:  Oman Med J       Date:  2014-05

2.  Can Behcet's Disease Related Pulmonary Arterial Aneurysms be Completely Resolved?

Authors:  Adnan Agha; Abdelhaleem M E Bella; Al-Hussain M Assiri; Mohammad Al-Hakami
Journal:  Open Rheumatol J       Date:  2011-11-29

3.  Managing Behçet's disease: An update on current and emerging treatment options.

Authors:  P La van Daele; J H Kappen; P M van Hagen; J Am van Laar
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.